---
title: "Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280868121.md"
description: "Quoin Pharmaceuticals Ltd (QNRX) has revealed increased financing risks due to covenants in its October 2025 Purchase Agreement, which restrict variable rate financings until April 2026 and equity financings below the unit price until June 2026. These limitations, along with a 25% participation right for October Purchasers, may hinder the company's ability to secure necessary funding, leading to potential program delays or terminations that could adversely affect its business. The average stock price target for QNRX is $37.50, indicating a potential upside of 485.02%."
datetime: "2026-03-28T06:00:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280868121.md)
  - [en](https://longbridge.com/en/news/280868121.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280868121.md)
---

# Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays

Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Debt & Financing category.

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Quoin Pharmaceuticals Ltd. faces heightened financing risk because the October 2025 Purchase Agreement restricts variable rate financings until April 12, 2026, and equity financings below the October 2025 unit price until June 2, 2026. These covenants, combined with the October Purchasers’ 25% participation right, may limit its ability to secure timely, acceptable funding, potentially forcing program delays or terminations that could materially harm its business and financial condition.

The average QNRX stock price target is $37.50, implying 485.02% upside potential.

To learn more about Quoin Pharmaceuticals Ltd’s risk factors, click here.

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [QNRX.US](https://longbridge.com/en/quote/QNRX.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)